The mTOR pathway negatively controls ATM by up-regulating miRNAs

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 29, 2013, Pages 11869-11874

  Shen, Changxian ^a   Houghton, Peter J ^a  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Childhood cancer; Kinase inhibitor

Indexed keywords

ATM PROTEIN; AZD 8055; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MICRORNA; MICRORNA 18A; MICRORNA 421; RAPAMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE CONTROL; GENE TARGETING; HUMAN; HUMAN CELL; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SARCOMA; SARCOMA CELL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION;

CHILDHOOD CANCER; KINASE INHIBITOR;

ANIMALS; ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL CYCLE PROTEINS; CELLS, CULTURED; DNA-BINDING PROTEINS; FEEDBACK, PHYSIOLOGICAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; MICE; MICRORNAS; MORPHOLINES; PROTEIN-SERINE-THREONINE KINASES; SARCOMA; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84880367902     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1220898110     Document Type: Article

References (50)

1. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
2. Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: Oncogene and nononcogene addiction. Cell 136(5):823-837.
3. Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432(7015): 316-323.
4. Ciccia A, Elledge SJ (2010) The DNA damage response: Making it safe to play with knives. Mol Cell 40(2):179-204.
5. Levine AJ, Feng Z, Mak TW, You H, Jin S (2006) Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev 20(3): 267-275.
6. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124(3):471-484.
7. Feng Z, Levine AJ (2010) The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 20(7):427-434.
8. Feng Z, et al. (2007) The regulation of AMPK beta1, TSC2, and PTEN expression by p53: Stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res 67(7):3043-3053.
9. Feng Z, Zhang H, Levine AJ, Jin S (2005) The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 102(23):8204-8209.
10. Budanov AV, Karin M (2008) p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell 134(3):451-460.
11. Brugarolas J, et al. (2004) Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18(23): 2893-2904.
12. DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW (2008) Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 22(2):239-251.
13. Cam H, Easton JB, High A, Houghton PJ (2010) mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell 40(4): 509-520.
14. Salk JJ, Fox EJ, Loeb LA (2010) Mutational heterogeneity in human cancers: Origin and consequences. Annu Rev Pathol 5:51-75.
15. Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458(7239): 719-724.
16. Takai H, Wang RC, Takai KK, Yang H, de Lange T (2007) Tel2 regulates the stability of PI3K-related protein kinases. Cell 131(7):1248-1259.
17. Shaw RJ, Cantley LC (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441(7092):424-430.
18. Bjornsti MA, Houghton PJ (2004) The TOR pathway: A target for cancer therapy. Nat Rev Cancer 4(5):335-348.
19. Menon S, et al. (2012) Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal 5(217):ra24.
20. Houghton PJ, et al. (2012) Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer 58(2): 191-199.
21. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098-1101.
22. Lujambio A, Lowe SW (2012) The microcosmos of cancer. Nature 482(7385):347-355.
23. Iorio MV, Croce CM (2012) microRNA involvement in human cancer. Carcinogenesis 33(6):1126-1133.
24. Song L, et al. (2011) miR-18a impairs DNA damage response through downregulation of ataxia telangiectasia mutated (ATM) kinase. PLoS ONE 6(9):e25454.
25. Ng WL, Yan D, Zhang X, Mo YY, Wang Y (2010) Over-expression of miR-100 is responsible for the low-expression of ATM in the human glioma cell line: M059J. DNA Repair (Amst) 9(11):1170-1175.
26. Yan D, et al. (2010) Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS ONE 5(7):e11397.
27. Hu H, Du L, Nagabayashi G, Seeger RC, Gatti RA (2010) ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci USA 107(4):1506-1511.
28. Dews M, et al. (2006) Augmentation of tumor angiogenesis by a Myc-Activated microRNA cluster. Nat Genet 38(9):1060-1065.
29. Terrile M, et al. (2011) miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs. PLoS ONE 6(12):e28356.
30. Wei JS, et al. (2009) microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res 15(17):5560-5568.
31. Johnsen JI, et al. (2008) Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 27(20):2910-2922.
32. GustafsonWC, Weiss WA (2010) Myc proteins as therapeutic targets. Oncogene 29(9): 1249-1259.
33. Levine AJ, Oren M (2009) The first 30 years of p53: Growing ever more complex. Nat Rev Cancer 9(10):749-758.
34. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12(1):21-35.
35. Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7(8):606-619.
36. Vousden KH, Prives C (2009) Blinded by the light: The growing complexity of p53. Cell 137(3):413-431.
37. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8(4): 275-283.
38. Vogelstein B, Kinzler KW (1993) The multistep nature of cancer. Trends Genet 9(4): 138-141.
39. Holland AJ, Cleveland DW (2009) Boveri revisited: Chromosomal instability, aneuploidy and tumorigenesis. Nat Rev Mol Cell Biol 10(7):478-487.
40. Toffolatti L, et al. (2002) MYCN expression in human rhabdomyosarcoma cell lines and tumour samples. J Pathol 196(4):450-458.
41. Dias P, et al. (1990) N-myc gene is amplified in alveolar rhabdomyosarcomas (RMS) but not in embryonal RMS. Int J Cancer 45(4):593-596.
42. Ai L, et al. (2004) Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: Promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol Biomarkers Prev 13(1):150-156.
43. Bolt J, et al. (2005) The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms. Oral Oncol 41(10):1013-1020.
44. Zhang P, et al. (2003) Association of ataxia telangiectasia mutated (ATM) gene mutation/deletion with rhabdomyosarcoma. Cancer Biol Ther 2(1):87-91.
45. Hansford LM, et al. (2004) Mechanisms of embryonal tumor initiation: Distinct roles for MycN expression and MYCN amplification. Proc Natl Acad Sci USA 101(34): 12664-12669.
46. Varmus H (2006) The new era in cancer research. Science 312(5777):1162-1165.
47. Diffley JF (2010) The many faces of redundancy in DNA replication control. Cold Spring Harb Symp Quant Biol 75:135-142.
48. Bartkova J, et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434(7035):864-870.
49. Gorgoulis VG, et al. (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434(7035):907-913.
50. Houghton PJ, et al. (2008) Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50(4):799-805.